1. Home
  2. BBNX vs MYGN Comparison

BBNX vs MYGN Comparison

Compare BBNX & MYGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$16.49

Market Cap

493.1M

Sector

Health Care

ML Signal

HOLD

Logo Myriad Genetics Inc.

MYGN

Myriad Genetics Inc.

HOLD

Current Price

$5.98

Market Cap

444.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BBNX
MYGN
Founded
2015
1991
Country
United States
United States
Employees
423
N/A
Industry
Medical/Dental Instruments
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
493.1M
444.2M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
BBNX
MYGN
Price
$16.49
$5.98
Analyst Decision
Strong Buy
Buy
Analyst Count
10
7
Target Price
$23.80
$7.64
AVG Volume (30 Days)
1.1M
1.6M
Earning Date
04-21-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$771,400,000.00
Revenue This Year
$34.90
$6.86
Revenue Next Year
$34.63
$5.45
P/E Ratio
N/A
N/A
Revenue Growth
N/A
2.33
52 Week Low
$8.80
$3.53
52 Week High
$32.71
$8.59

Technical Indicators

Market Signals
Indicator
BBNX
MYGN
Relative Strength Index (RSI) 65.40 73.10
Support Level $16.02 $4.29
Resistance Level $32.52 $7.29
Average True Range (ATR) 1.07 0.31
MACD 0.14 0.15
Stochastic Oscillator 83.89 93.27

Price Performance

Historical Comparison
BBNX
MYGN

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

About MYGN Myriad Genetics Inc.

Myriad Genetics Inc is a molecular diagnostics and precision medicine company committed to advancing health and well-being for all. The company develops and commercializes molecular tests that help patients and providers uncover genetic insights. Its tests assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties, supporting earlier detection, more precise treatment, and lowering healthcare costs. Its tests include BRACAnalysis CDx, EndoPredict, FirstGene, Foresight, GeneSight, MyChoice CDx, MyRisk (cancer treatment), MyRisk (cancer risk), Prequel, Precise Tumor, Prolaris, and SneakPeek. The company operates in the US and Rest of World, with maximum revenue from the US.

Share on Social Networks: